Primary cell barrier function evaluation is an in vitro testing approach that quantifies how tightly epithelial and endothelial monolayers cultured directly from human or animal tissue restrict the passage of ions, molecules, and particles. Using endpoints such as transepithelial electrical resistance (TEER), paracellular permeability, and tight junction protein expression, accredited third-party laboratories support drug permeability studies, inhalation and chemical toxicology, and medical device biocompatibility assessment aligned with recognized ISO and GB frameworks. This article outlines the sample types, test items, methods, and applications of primary cell barrier function evaluation.
Technical Overview
Barrier function describes the ability of an epithelial or endothelial monolayer to act as a selective interface: it restricts paracellular diffusion through tight junctions while permitting controlled transcellular transport of nutrients, drugs, and signaling molecules. Primary cells, isolated directly from human or animal tissue and cultured without genetic immortalization, retain the donor-specific junctional architecture, transporter expression, and metabolic activity of the tissue of origin, which makes them substantially more physiologically relevant than continuously passaged cell lines for barrier studies.
Primary cell barrier function evaluation is performed on permeable membrane inserts that allow cells to polarize into distinct apical and basolateral compartments. Airway models are commonly differentiated at an air–liquid interface to develop cilia and mucus production, while endothelial models may be co-cultured with astrocytes or pericytes to recapitulate inductive barrier signals. Functional integrity is quantified through an integrated endpoint panel — transepithelial or transendothelial electrical resistance (TEER), paracellular permeability marker flux, tight junction protein expression and localization, viability, and inflammatory mediator release — generating data applicable to drug permeability screening, inhalation and chemical toxicology, cosmetic safety, and medical device biocompatibility programs aligned with the ISO 10993 series and its GB/T 16886 counterpart. Studies are routinely conducted by accredited third-party laboratories operating under ISO/IEC 17025 quality management systems.
Testing Samples
Primary Respiratory Epithelial Models
Normal human bronchial epithelial cells and small airway epithelial cells are seeded on collagen-coated inserts and differentiated at an air–liquid interface for three to four weeks until ciliated, mucus-secreting monolayers form. These models are used to evaluate inhaled pharmaceuticals, nebulized formulations, e-cigarette aerosols, and ambient or occupational air pollutants.
Primary Intestinal Epithelial Models
Primary human enterocytes or colonocytes, including monolayers derived from intestinal organoids, reproduce donor-specific permeability and transporter phenotypes. They are applied to oral drug absorption prediction, excipient and food ingredient bioavailability studies, and gut barrier toxicity assessment.
Primary Blood–Brain Barrier Models
Primary brain microvascular endothelial cells, frequently co-cultured with astrocytes and pericytes, generate the tightest endothelial barrier achievable in vitro. They are used to estimate central nervous system penetration of drug candidates and the neurotoxic potential of environmental chemicals.
Primary Renal, Corneal, and Mucosal Models
Renal proximal tubule epithelial cells, corneal and conjunctival epithelial cells, oral mucosal cells, retinal pigment epithelial cells, and ectocervical epithelial cells are cultured on inserts to characterize tissue-specific barrier behavior for nephrotoxicity, ocular penetration, and mucosal delivery applications.
Test Articles and Extracts
Typical test articles include pharmaceutical compounds and formulations, medical device extracts prepared according to ISO 10993-12, cosmetics and consumer product ingredients, industrial chemicals, nanomaterial dispersions, and aerosols or gases delivered through air–liquid interface exposure systems. Dosing is performed on the apical side to mimic physiological exposure, with parallel basolateral dosing when systemic exposure is simulated.
Testing Items
Barrier function evaluation packages are assembled from complementary functional, molecular, and cytotoxic endpoints:
- Transepithelial or transendothelial electrical resistance (TEER), reported in ohms per square centimeter.
- Paracellular permeability measured with integrity probes such as Lucifer yellow, sodium fluorescein, mannitol, and FITC-dextran of graded molecular weights.
- Apparent permeability coefficients (Papp) and bidirectional efflux ratios for test compounds.
- Expression and junctional localization of tight junction proteins, including ZO-1, occludin, claudin isoforms, JAM-A, and tricellulin, assessed by immunofluorescence, Western blotting, or quantitative PCR.
- Monolayer morphology, confluence, and F-actin cytoskeletal organization.
- Cell viability and cytotoxicity using MTT, resazurin, or ATP assays together with LDH release, interpreted against the 70 percent viability threshold commonly applied in ISO 10993-5 cytotoxicity testing.
- Barrier recovery kinetics after removal of a disruptive treatment.
- Inflammatory mediator secretion, including IL-6, IL-8, and TNF-alpha.
- Transporter functional activity, such as P-glycoprotein-mediated efflux.
- Oxidative stress markers, including reactive oxygen species generation and mitochondrial function.
Testing Methods
Culture establishment and qualification: primary cells are seeded onto collagen- or fibronectin-coated permeable supports with 0.4 micrometer pores, or 1.0 micrometer pores where cell-cell contact in co-culture is required. Monolayers are qualified before dosing based on stable TEER plateau values across at least three consecutive measurement days, confirmed confluence, absence of mycoplasma by PCR, and strict passage-number limits to preserve phenotype.
TEER measurement: resistance is measured with a voltohmmeter equipped with chopstick or stationary chamber electrodes, with blank insert resistance subtracted and the net value multiplied by the membrane growth area to yield ohms per square centimeter. Measurements are taken before, during, and after exposure to construct time-course profiles. Calcium chelation with EDTA or EGTA and junction-disrupting agents serve as positive controls that confirm assay responsiveness.
Permeability quantification: integrity probes or test compounds are dosed into the apical donor compartment, and receiver compartment samples are collected at serial time points with volume replacement to maintain hydrodynamic balance. Fluorescence or radiometric quantification supports calculation of Papp as the rate of compound appearance in the receiver chamber divided by membrane area and initial donor concentration. Sink conditions are verified and mass balance is maintained within 80 to 120 percent, while bidirectional assays generate efflux ratios that flag active transport involvement.
Molecular and morphological endpoints: confocal immunofluorescence is used to score the continuity of ZO-1 and claudin staining at cell borders, complemented by Western blot or quantitative PCR for total protein and transcript abundance. Viability and LDH assays are run in parallel so that genuine barrier modulation can be distinguished from nonspecific cytotoxicity.
Data handling and quality assurance: multiple independent donors are recommended to capture inter-donor variability, and batch acceptance criteria, instrument calibration, and traceable documentation are applied throughout. Many sponsors engage accredited third-party laboratories with ISO/IEC 17025-accredited quality systems to ensure reproducibility and data integrity for regulatory-facing submissions.
Applications
Primary cell barrier function data inform decisions across pharmaceutical, chemical, medical device, and consumer product development:
- Prediction of oral and pulmonary drug absorption, lead optimization, and formulation comparison.
- Inhalation toxicology for air pollutants, occupational aerosols, and inhaled consumer products under air–liquid interface exposure.
- Blood–brain barrier penetration assessment and central nervous system safety evaluation.
- Biocompatibility and leachables evaluation of medical devices in support of ISO 10993 and GB/T 16886 test programs.
- Safety testing of cosmetics, household chemicals, and food contact materials as animal-free alternatives.
- Nanomaterial and advanced material hazard characterization.
- Disease modeling and personalized medicine using donor-derived monolayers, including asthma, COPD, and inflammatory bowel disease research.
- Bioavailability assessment of functional foods and nutraceutical ingredients.
FAQ
Why use primary cells instead of immortalized cell lines?
Primary cells preserve donor genotype, native tight junction composition, and physiological transporter and metabolic activity, so barrier responses better reflect tissue behavior. Cell lines remain useful for high-throughput screening, but primary models reduce false positives and improve translational relevance at critical decision points.
What TEER value indicates a functional barrier?
Thresholds are model dependent: differentiated airway cultures commonly reach several hundred ohms per square centimeter, blood–brain barrier co-cultures can exceed one thousand, and intestinal monolayers are inherently leakier. What matters most is a stable plateau specific to the model, an acceptably low marker flux, and a validated response to positive disruption controls.
How long does monolayer differentiation take?
Airway epithelia typically require 21 to 28 days at an air–liquid interface for full differentiation, blood–brain barrier models 7 to 14 days, and renal or corneal monolayers roughly 5 to 10 days. Dosing begins only after qualification criteria are met.
Which standards apply to this testing?
The ISO 10993 series and its GB/T 16886 counterpart govern cytotoxicity interpretation and sample preparation for medical device contexts, while ISO/IEC 17025 defines laboratory competence requirements. Protocol design also draws on internationally recognized best practices for in vitro permeability and epithelial transport studies.
How is donor variability managed?
Replicate donors are tested, data are reported both by donor and as pooled summaries, and inclusion criteria define acceptable baseline TEER and marker flux. This design reveals whether a response is donor specific or robust across the population.
Can the data support regulatory submissions?
Yes. Barrier function endpoints are accepted as supportive in vitro evidence in weight-of-evidence safety packages, biocompatibility files, and absorption or toxicology justifications. Sponsors should confirm jurisdiction-specific requirements and consider studies executed by accredited third-party laboratories under appropriate quality systems.
